Andrew Schiermeier is the founder of AvenCell. AvenCell has raised $362M in total funding. Latest round: Series B. Based in Watertown, Massachusetts.
Andrew Schiermeier, PhD, is the President and CEO of AvenCell Therapeutics, a clinical-stage biopharma company specializing in switchable universal T-cell therapies for challenging cancers. He leads the company, which was founded with $250 million in committed capital from Blackstone Life Sciences as its sole founding investor. Schiermeier previously held leadership roles at Cellex Cell Professionals, which contributed technology to AvenCell's pipeline.
Full founder directory · Investor directory · Company funding database · Fundraising library